Intentar ORO - Gratis
APAC Vaccine Powerhouses Flex Capacity & Quality Muscle
BioSpectrum Asia
|BioSpectrum Asia May 2025
Asia is the epicentre of global vaccine manufacturing, with India and China together supplying over a billion doses annually. Now, emerging players like South Korea, Singapore, and Australia are stepping up, investing in next-gen platforms and expanding capacity to meet global demand. Let's map the manufacturing footprint of Asia's leading vaccine manufacturers, tracking their current capacity, expansion plans, and the strategic shifts that are transforming the region into a global vaccine production hub.
Asia-Pacific is driving a transformation in the global vaccine supply landscape. According to the WHO Vaccine Report 2024, the WHO South-East Asia region now self-supplies 87 per cent of its vaccines—thanks largely to India, which accounts for 84 per cent of the doses procured in the region and produces 99 per cent of its requirements. Similarly, in the Western Pacific region, China supplies 54 per cent of vaccines and meets 90 per cent of its domestic demand. Manufacturers affiliated with the Developing Countries Vaccine Manufacturers Network (DCVMN) accounted for 54 per cent of global vaccine volumes sold in 2023, further emphasising the role of emerging economies in shaping vaccine access. Together, these two countries are not only meeting regional needs but are scaling up rapidly, with production capacities growing by 15—20 per cent annually. At the same time, Asia as a whole manufacturing base is broadening. The number of companies producing between 10 and 100 million doses annually has jumped from 28 in 2019 to 42 in 2023, with half of this growth coming from China.
While India and China remain the undisputed leaders in vaccine manufacturing, other countries in the Asia-Pacific region are stepping up. South Korea has carved out an impressive niche playing a key role in the global COVAX initiative by supplying vaccines to lower-income countries. Japan and Singapore have focused on high-value, specialised vaccines, with Japanese manufacturers particularly strong in regulated markets like North America and Europe. APAC has a diverse manufacturing ecosystem, while private companies dominate in India and China, government-run manufacturers play a vital role in countries like Thailand, the Philippines, Indonesia, and Vietnam.
Esta historia es de la edición BioSpectrum Asia May 2025 de BioSpectrum Asia.
Suscríbete a Magzter GOLD para acceder a miles de historias premium seleccionadas y a más de 9000 revistas y periódicos.
¿Ya eres suscriptor? Iniciar sesión
MÁS HISTORIAS DE BioSpectrum Asia
BioSpectrum Asia
India–EU FTA Paves Way for Expanded Healthcare Trade
On January 27, 2026, after years of negotiations, India and the European Union announced a landmark Free Trade Agreement.
4 mins
BioSpectrum Asia March 2026
BioSpectrum Asia
PreferCo and Glatt to open CoE for precision fermentation bioprocess scale-up in India
In a major boost to Government of India's BioE3 push, German major Glatt and India-based startup PreferCo have announced the launch of \"PreferCo-Glatt Centre of Excellence (CoE) for Bioprocess Scale-Up\" in Hyderabad's Genome Valley.
1 min
BioSpectrum Asia March 2026
BioSpectrum Asia
Women's Health Surge in APAC
The rising burden of diseases such as ovarian cancer, breast cancer, cervical cancer, infertility, etc. is emerging as the key driver of the women's healthcare market across the globe. While North America led the women healthcare market in 2025, Asia Pacific (APAC) is expected to witness the fastest growth this year onwards. As a result, governments across the APAC region, are recognising the importance of women's health and are launching initiatives, particularly under female leaders, to improve access to healthcare services. Moreover, a number of women-led startups are now developing new solutions to address this growing burden of women-associated diseases in the APAC region. Let's take a closer look.
6 mins
BioSpectrum Asia March 2026
BioSpectrum Asia
Hanchor Bio receives US FDA Orphan Drug Designation for HCB101 in gastric cancer
Taiwan-based biotech startup HanchorBio, Inc. has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to HCB101 for the treatment of gastric cancer.
1 min
BioSpectrum Asia March 2026
BioSpectrum Asia
Daiichi Sankyo names Dr John Tsai as Global Head of R&D
Japan-based Daiichi Sankyo Company has appointed Dr John Tsai to succeed Dr Ken Takeshita, who is stepping down as Global Head of R&D, effective April 1, 2026.
1 min
BioSpectrum Asia March 2026
BioSpectrum Asia
"The global trend is moving beyond centralised hubs toward distributed networks and domestic capability"
King Faisal Specialist Hospital & Research Centre (KFSHRC) and US-based Germfree Laboratories have announced a strategic partnership to develop Saudi Arabia's first fully integrated, modular Advanced Therapy Medicinal Product (ATMP) Manufacturing Campus.
4 mins
BioSpectrum Asia March 2026
BioSpectrum Asia
SEOUL'S RISKY DRUG PRICING RESET
Drug pricing has once again moved to the centre of policy debate in South Korea, with the government recently stepping back from its proposed generic drug pricing reform.
2 mins
BioSpectrum Asia March 2026
BioSpectrum Asia
Takeda and Iambic sign $1.7 B deal to advance AI driven design of small molecules
Iambic, a US-based clinical-stage life science and technology company developing novel medicines using its artificial intelligence (AI)-driven discovery and development platform, has announced a multi-year technology and discovery collaboration agreement with Japan-based Takeda Pharma that will use Iambic's industry leading AI drug discovery models to advance a select set of high-priority small molecule programmes, initially in Takeda's Oncology and Gastrointestinal and Inflammation therapeutic areas.
1 min
BioSpectrum Asia March 2026
BioSpectrum Asia
S.Biomedics announces partnership with Catalent to develop and manufacture TED-A9
US-based Catalent and South Korea-based S.Biomedics have announced a strategic partnership to support the development and manufacturing of TED-A9, S.Biomedics' allogeneic pluripotent stem-cell-derived ventral midbrain-specific dopaminergic precursor cell therapy being developed for the treatment of Parkinson's disease.
1 min
BioSpectrum Asia March 2026
BioSpectrum Asia
China revises drug administration regulations to spur innovation
China has revised regulations concerning drug administration in a bid to promote drug innovation, strengthen management of online sales of medicines and reinforce drug safety supervision.
1 min
BioSpectrum Asia March 2026
Listen
Translate
Change font size

